Novartis

News

Mission successful for Novartis after FDA approves ofatumuma...

It’s mission accomplished for Novartis after the FDA approved ofatumumab for multiple sclerosis, completing a project where the former cancer drug has been repurposed.

News

Roche takes on pricey rivals as FDA approves SMA drug

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam).

Podcasts

Novartis, company culture and COVID-19: the pharmaphorum pod...

Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future.

News

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

News

Novartis takes $485m hit after axing eczema drug from pipeli...

Novartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process.

News

Biogen plans trial of Spinraza in patients not responding to...

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded properly to Novartis' gene therapy Zolgensma, combining the two ultra-expensiv

Mission successful for Novartis after FDA approves ofatumuma...

Roche takes on pricey rivals as FDA approves SMA drug

Novartis, company culture and COVID-19: the pharmaphorum pod...

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Novartis takes $485m hit after axing eczema drug from pipeli...

Biogen plans trial of Spinraza in patients not responding to...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks